Suppr超能文献

基于钯催化的交叉偶联反应的 8-硝基喹啉-2(1H)-酮骨架 3 位的抗锥虫药物修饰

Antitrypanosomatid Pharmacomodulation at Position 3 of the 8-Nitroquinolin-2(1H)-one Scaffold Using Palladium-Catalysed Cross-Coupling Reactions.

机构信息

LCC-CNRS, Université de Toulouse, CNRS, UPS, 205 route de Narbonne, 31077, Toulouse, France.

Université de Limoges, UMR INSERM 1094, Neuroépidémiologie Tropicale, Faculté de Pharmacie, 2 rue du Dr Marcland, 87025, Limoges, France.

出版信息

ChemMedChem. 2018 Oct 22;13(20):2217-2228. doi: 10.1002/cmdc.201800456. Epub 2018 Sep 17.

Abstract

An antikinetoplastid pharmacomodulation study at position 3 of the recently described hit molecule 3-bromo-8-nitroquinolin-2(1H)-one was conducted. Twenty-four derivatives were synthesised using the Suzuki-Miyaura cross-coupling reaction and evaluated in vitro on both Leishmania infantum axenic amastigotes and Trypanosoma brucei brucei trypomastigotes. Introduction of a para-carboxyphenyl group at position 3 of the scaffold led to the selective antitrypanosomal hit molecule 3-(4-carboxyphenyl)-8-nitroquinolin-2(1H)-one (21) with a lower reduction potential (-0.56 V) than the initial hit (-0.45 V). Compound 21 displays micromolar antitrypanosomal activity (IC =1.5 μm) and low cytotoxicity on the human HepG2 cell line (CC =120 μm), having a higher selectivity index (SI=80) than the reference drug eflornithine. Contrary to results previously obtained in this series, hit compound 21 is inactive toward L. infantum and is not efficiently bioactivated by T. brucei brucei type I nitroreductase, which suggests the existence of an alternative mechanism of action.

摘要

对最近描述的命中分子 3-溴-8-硝基喹啉-2(1H)-酮在位置 3 进行了抗动力原生质体药物修饰研究。使用 Suzuki-Miyaura 交叉偶联反应合成了 24 种衍生物,并在体外对利什曼原虫无鞭毛体和布氏锥虫布氏锥虫鞭毛体进行了评估。在支架的 3 位引入对羧苯基,得到了选择性抗锥虫的命中分子 3-(4-羧苯基)-8-硝基喹啉-2(1H)-酮(21),其还原电位(-0.56 V)低于初始命中分子(-0.45 V)。化合物 21 对人体 HepG2 细胞系具有微摩尔抗锥虫活性(IC =1.5 μm)和低细胞毒性(CC =120 μm),其选择性指数(SI=80)高于参考药物依氟鸟氨酸。与该系列先前获得的结果相反,命中化合物 21对 L. infantum 无效,并且不能被 T. brucei brucei 型 I 硝基还原酶有效生物转化,这表明存在替代作用机制。

相似文献

3
Novel 8-nitroquinolin-2(1H)-ones as NTR-bioactivated antikinetoplastid molecules: Synthesis, electrochemical and SAR study.
Eur J Med Chem. 2018 Jul 15;155:135-152. doi: 10.1016/j.ejmech.2018.06.001. Epub 2018 Jun 5.
4
Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.
Bioorg Med Chem. 2015 May 15;23(10):2377-86. doi: 10.1016/j.bmc.2015.03.064. Epub 2015 Mar 31.
5
8-Alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T. b. brucei and cruzi.
Eur J Med Chem. 2020 Sep 15;202:112558. doi: 10.1016/j.ejmech.2020.112558. Epub 2020 Jul 8.
6
New 8-Nitroquinolinone Derivative Displaying Submicromolar Activities against Both and .
ACS Med Chem Lett. 2020 Feb 6;11(4):464-472. doi: 10.1021/acsmedchemlett.9b00566. eCollection 2020 Apr 9.
7
Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents.
J Med Chem. 2012 Jun 14;55(11):5554-65. doi: 10.1021/jm300508n. Epub 2012 May 23.
9
Synthesis and antikinetoplastid activities of 3-substituted quinolinones derivatives.
Eur J Med Chem. 2012 Jun;52:44-50. doi: 10.1016/j.ejmech.2012.03.003. Epub 2012 Mar 16.
10
Discovery of a new antileishmanial hit in 8-nitroquinoline series.
Eur J Med Chem. 2012 Aug;54:75-86. doi: 10.1016/j.ejmech.2012.04.029. Epub 2012 May 2.

引用本文的文献

1
The Potential of 2-Substituted Quinolines as Antileishmanial Drug Candidates.
Molecules. 2022 Apr 2;27(7):2313. doi: 10.3390/molecules27072313.
2
New 8-Nitroquinolinone Derivative Displaying Submicromolar Activities against Both and .
ACS Med Chem Lett. 2020 Feb 6;11(4):464-472. doi: 10.1021/acsmedchemlett.9b00566. eCollection 2020 Apr 9.

本文引用的文献

1
Novel 8-nitroquinolin-2(1H)-ones as NTR-bioactivated antikinetoplastid molecules: Synthesis, electrochemical and SAR study.
Eur J Med Chem. 2018 Jul 15;155:135-152. doi: 10.1016/j.ejmech.2018.06.001. Epub 2018 Jun 5.
2
Current and Future Prospects of Nitro-compounds as Drugs for Trypanosomiasis and Leishmaniasis.
Curr Med Chem. 2019;26(23):4454-4475. doi: 10.2174/0929867325666180426164352.
3
Design, synthesis, and antiprotozoal evaluation of new 2,9-bis[(substituted-aminomethyl)phenyl]-1,10-phenanthroline derivatives.
Chem Biol Drug Des. 2018 May;91(5):974-995. doi: 10.1111/cbdd.13164. Epub 2018 Jan 17.
4
Synthesis, characterization, and antileishmanial activity of neutral N-heterocyclic carbenes gold(I) complexes.
Eur J Med Chem. 2018 Jan 1;143:1635-1643. doi: 10.1016/j.ejmech.2017.10.060. Epub 2017 Oct 24.
6
Human African trypanosomiasis.
Lancet. 2017 Nov 25;390(10110):2397-2409. doi: 10.1016/S0140-6736(17)31510-6. Epub 2017 Jun 30.
7
Leishmaniasis drug discovery: recent progress and challenges in assay development.
Drug Discov Today. 2017 Oct;22(10):1516-1531. doi: 10.1016/j.drudis.2017.06.004. Epub 2017 Jun 21.
8
Identification of Trypanosoma brucei AdoMetDC Inhibitors Using a High-Throughput Mass Spectrometry-Based Assay.
ACS Infect Dis. 2017 Jul 14;3(7):512-526. doi: 10.1021/acsinfecdis.7b00022. Epub 2017 Apr 7.
9
Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need.
Nat Rev Microbiol. 2017 Feb 27;15(4):217-231. doi: 10.1038/nrmicro.2016.193.
10
Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in Leishmania.
PLoS Pathog. 2016 Nov 3;12(11):e1005971. doi: 10.1371/journal.ppat.1005971. eCollection 2016 Nov.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验